about
Use of complementary and alternative medicine by children in Europe: published data and expert perspectives.Pricing and Reimbursement of Biosimilars in Central and Eastern European CountriesEconomic evaluation of continuous subcutaneous insulin infusion for children with diabetes - a pilot study: CSII application for children - economic evaluation.Health technology assessment in the Balkans: opportunities for a balanced drug assessment systemISO 9001 certification for hospitals in Bulgaria: does it help service?Comparison of health-related quality-of-life measurement instruments in diabetic patients.Use of biologics for psoriasis in Central and Eastern European countries.The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications.Chronic Hepatitis C-Related Cirrhosis Hospitalization Cost Analysis in Bulgaria.EQ-5D studies in musculoskeletal and connective tissue diseases in eight Central and Eastern European countries: a systematic literature review and meta-analysis.Cost of severe hypoglycaemia in nine European countries.Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation.Policies for biosimilar uptake in Europe: An overview.Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European countries.EQ-5D studies in cardiovascular diseases in eight Central and Eastern European countries: a systematic review of the literature.Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review.Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts.Comparative Price Analysis of Biological Products for Treatment of Rheumatoid ArthritisThe European challenges of funding orphan medicinal productsReal World Experience of Disease Activity in Patients With Rheumatoid Arthritis and Response to Treatment With Varios Biologic DMARDsBarriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited BudgetsComparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European CountriesCost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not on Dialysis in BulgariaQuality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological MedicinesProposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTAPharmacotherapeutic interventions for bipolar disorder type II: addressing multiple symptoms and approaches with a particular emphasis on strategies in lower and middle-income countriesEQ-5D studies in nervous system diseases in eight Central and East European countries: a systematic literature reviewLife expectancy and survival analysis of patients with diabetes compared to the non diabetic population in BulgariaComparative analysis of the access to health-care services and breast cancer therapy in 10 Eastern European countries
P50
Q30615456-80875A55-2392-4348-B05D-814E49826B41Q33775526-1058F62A-65A8-4898-ABDD-96495BCB2037Q35002517-AF66E665-55AF-4D4D-A2FB-B0F6B9C17006Q35613393-A52D0F94-7C9C-498E-B482-6AA9D7E99467Q35613957-9CA5150D-F759-41BA-9C08-8D70DC000297Q35613977-80EFDE1B-6072-4CDE-B574-5FB966D98DA8Q38586836-0102A8CC-2F54-4556-9BC7-03CF70CFB971Q38610858-30013079-48D5-4ABF-BC27-63BE5759816EQ38616536-BB77CB87-0B83-4899-A608-8BE0124EABBFQ38636348-B1834193-4F7B-4AC3-AB54-BC31A2FF7B5CQ39779773-8B0BA9BA-B8E8-49E5-B5B3-EE452358C6F6Q41526451-EFF2BF16-3D8C-43F0-A1C7-58CA614793ECQ47173303-EDE663DF-E72C-4E1E-85A1-41694FA4A668Q47553245-25FC7E0A-3719-4B55-BCDE-22F6B7E2D862Q48513894-F0FC0D07-D7D3-4A81-8D48-89FF7B61048CQ49733211-1B32E11C-1A9C-4FF5-9C33-0413487B395DQ55212098-B659F2E4-E7F3-47E5-A83B-D3EBED18295CQ57191804-A0C5D260-F20C-4BFF-BC37-43937FDB8E8FQ58608363-6A8A1448-93D4-4998-A353-2F8B044480FAQ59791952-69D6EE92-36DC-4ECA-851B-8A445435CF1BQ60046512-3B5696F4-94DD-4EEC-8FB2-B849B30E3752Q64043899-09F48AE2-F8BF-474E-A8EC-02EF18F1B89CQ88482345-B5620396-E994-4485-B4DF-69D2632A5079Q90725448-AB73A7F5-43A7-4DAC-8A1E-BA80C17D3330Q91270630-AB1E089C-D3EE-4478-A3F9-6696BAD30886Q91425330-DFFA2706-992E-485C-9ED6-9EC377518E84Q92102042-4DC8F9E1-6B95-43EE-9547-47C604977A4BQ94552963-5AA1B3D7-0F93-45D3-B461-6B412CBE4B74Q96434469-91D3FB87-55E3-44C7-857E-AE4C5A930E0E
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
G Petrova
@ast
G Petrova
@en
G Petrova
@es
G Petrova
@nl
type
label
G Petrova
@ast
G Petrova
@en
G Petrova
@es
G Petrova
@nl
prefLabel
G Petrova
@ast
G Petrova
@en
G Petrova
@es
G Petrova
@nl
P106
P1153
7102471801
P31
P496
0000-0001-8116-5138